FK228 analogues induce fetal hemoglobin in human erythroid progenitors

Levi Makala, Salvatore Di Maro, Tzu Fang Lou, Sharanya Sivanand, Jung Mo Ahn, Betty S. Pace

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD.

Original languageEnglish (US)
Article number428137
JournalAnemia
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Fetal Hemoglobin
Sickle Cell Anemia
Luciferases
romidepsin
Research
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

Makala, L., Di Maro, S., Lou, T. F., Sivanand, S., Ahn, J. M., & Pace, B. S. (2012). FK228 analogues induce fetal hemoglobin in human erythroid progenitors. Anemia, 2012, [428137]. https://doi.org/10.1155/2012/428137

FK228 analogues induce fetal hemoglobin in human erythroid progenitors. / Makala, Levi; Di Maro, Salvatore; Lou, Tzu Fang; Sivanand, Sharanya; Ahn, Jung Mo; Pace, Betty S.

In: Anemia, Vol. 2012, 428137, 2012.

Research output: Contribution to journalArticle

Makala, L, Di Maro, S, Lou, TF, Sivanand, S, Ahn, JM & Pace, BS 2012, 'FK228 analogues induce fetal hemoglobin in human erythroid progenitors', Anemia, vol. 2012, 428137. https://doi.org/10.1155/2012/428137
Makala, Levi ; Di Maro, Salvatore ; Lou, Tzu Fang ; Sivanand, Sharanya ; Ahn, Jung Mo ; Pace, Betty S. / FK228 analogues induce fetal hemoglobin in human erythroid progenitors. In: Anemia. 2012 ; Vol. 2012.
@article{0d6812c36bc14875a767ee641da809f8,
title = "FK228 analogues induce fetal hemoglobin in human erythroid progenitors",
abstract = "Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD.",
author = "Levi Makala and {Di Maro}, Salvatore and Lou, {Tzu Fang} and Sharanya Sivanand and Ahn, {Jung Mo} and Pace, {Betty S.}",
year = "2012",
doi = "10.1155/2012/428137",
language = "English (US)",
volume = "2012",
journal = "Anemia",
issn = "2090-1267",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - FK228 analogues induce fetal hemoglobin in human erythroid progenitors

AU - Makala, Levi

AU - Di Maro, Salvatore

AU - Lou, Tzu Fang

AU - Sivanand, Sharanya

AU - Ahn, Jung Mo

AU - Pace, Betty S.

PY - 2012

Y1 - 2012

N2 - Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD.

AB - Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD.

UR - http://www.scopus.com/inward/record.url?scp=84873876006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873876006&partnerID=8YFLogxK

U2 - 10.1155/2012/428137

DO - 10.1155/2012/428137

M3 - Article

VL - 2012

JO - Anemia

JF - Anemia

SN - 2090-1267

M1 - 428137

ER -